Governments, philanthropies and public health institutions increasingly recognize that new antibiotics will not emerge from the pharmaceutical pipeline if things are just "left to the market". Over the last five years, numerous investments have emerged to address the lack of novel antibiotics that are urgently needed to address drug-resistant infections.
ReAct has welcomed these efforts to address this market failure. Yet we are concerned that these efforts may not achieve the desired outcome of creating a sustainable new approach to antibiotic research and development. In a new policy paper, we outline the public health principles that should govern any public funding spent, to secure equitable and sustainable access to new antibiotics.
We need to create an “end-to-end” model for sustainable development of new antibiotics, to secure access for those that should be at the center – patients. This means we need to consider how access to and stewardship of these drugs will be handled, already when money is being invested in developing them.
Three key points why we need public health principles for sustainable access to novel antibiotics
1. An effective end to end model should not focus on the multinational pharmaceutical industry as the solution to a crisis that it played a role in causing.
Instead policy makers and donors must support a novel, alternative ecosystem which includes emerging biotechnology companies, generics companies, product development partnerships and the public sector.
2. As public sector funding is needed both to pay for the development of new antibiotics and for reimbursement once such products are approved, public health principles should govern the development of new antibiotics to safeguard public interest.
3. These public health principles include:
- Setting target product profiles for new products through scientific consensus.
- Ensuring full transparency across the pharmaceutical value chain.
- Promoting full delinkage to facilitate equitable and affordable access to new medicines.
Full delinkage: delinking the cost of investment in research and development from the price and volume of sales.
Achieving these in practice is difficult, but they should be principles all policy makers and donors set as achievable aspirations over time.
Need for substantial new resources from governments
It is clear that there is a need for substantial, new resources from governments (beyond what has already been committed), but we also caution that such resources could be wasted unless they are guided by public health principles. It needs to be made much clearer that investments made should not focus on large pharmaceutical companies, but ensure that research and development produces novel antibiotics that are affordable and accessible worldwide.
Full ReAct policy brief
More news and opinion from 2019
- ReAct’s 2019 wrap up and 2020 expectations
- Blog post by UNDP and ReAct: Antimicrobial resistance: An emerging crisis
- Water, sanitation and hygiene services critical to curbing antibiotic quick fix
- Diagnostics: Antibiotic susceptibility
- ReAct highlights during World Antibiotic Awareness week 2019
- 2019 AMR photo competition prizes announced
- Launch of UNICEF’s institutional guidance on antimicrobial resistance
- Proposed ban on colistin for animal use announced in Indonesia
- School children led celebration of World Toilet Day and World Antibiotic Awareness Week
- 10 Innovate4AMR-winning teams enjoyed 3-day workshop in Geneva
- After 4 collaborative meeting days: Actions for the future in Latin America
- Four key points from joint comments to One Health Global Leaders Group on AMR
- Why are children more vulnerable to AMR?
- Dr Yoel Lubell, Health Economist, on Thailand, AMR, UCH and cultural factors driving AMR
- UHC and AMR: The Thai Experience
- Why do effective antibiotics matter for quality of care and patient safety?
- New ReAct policy brief: Antimicrobial resistance and universal health coverage – What’s the deal?
- Three key takeaways from the ReAct Africa conference
- Diagnostics: Species identification
- AMR-specific indicator proposed for monitoring Sustainable Development Goals
- Five focus areas at the 2nd Ministerial Conference on AMR hosted by the Netherlands
- Safety concerns of fecal microbiota transplants
- Upcoming ReAct Africa Conference: universal health coverage and antimicrobial resistance in focus
- Mother Earth conference in Argentina – the environment in focus
- Diagnostics: What are we talking about?
- Connecting global to local civil-society-agenda on AMR at CSO convening in Geneva
- ReAct colleagues featured in WHO Bulletin as leading profiles in the work on reacting to antibiotic resistance
- RAN stakeholder at WHO IPC consultation – for standards and guidelines in African Union member states
- WHA conversation on Antibiotic Resistance as a Global Development Problem co-organized by ReAct
- Insights from ReAct Asia Pacific project on antibiotic stewardship in secondary level hospitals in India
- Open letter to UN Member States from former IACG members Anthony So and Otto Cars
- ReAct UHC Intervention at UNGA Multi-stakeholder Hearing for High-level Meeting on UHC
- ReAct Latin America honors Earth Day
- Medicines Patent Pool’s view on the role of licenses for antibiotics – World Intellectual Property Day
- Second time for Innovate4AMR competition!
- World Health Day 2019: Universal Health Coverage
- Diagnostics: Constraints for successful implementation
- Antibiotic Shortages: magnitude, causes and possible solutions: A new WHO meeting report
- Erry Setyawan, FAO, on Indonesian NAP: We need to work together to make it possible to manage AMR
- ReAct’s new 5-year strategic plan receives funding from Sida
- How infections spread and how to stop them
- Generating data for policy and practice